Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR4 | P61073 | 4/20 | 0.40 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | VDR | P11473 | 1/20 | 0.39 |
| ▸ | SSTR2 | P30874 | 5/20 | 0.39 |
| ▸ | SSTR1 | P30872 | 4/20 | 0.39 |
| ▸ | SSTR4 | P31391 | 4/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 4/20 | 0.39 |
| ▸ | SSTR5 | P35346 | 4/20 | 0.39 |
| ▸ | F12 | P00748 | 2/20 | 0.38 |
| ▸ | TFPI | P10646 | 2/20 | 0.37 |
| ▸ | TSLP | Q969D9 | 1/20 | 0.37 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24155284 | 0.94 | TNFSF11 (0.38) | CXCR4TNFSF11CACNA1BSSTR2SSTR1 | |
| SCHEMBL24155481 | 0.93 | TNFSF11 (0.37) | CXCR4TNFSF11CACNA1BSSTR2SSTR1 | |
| SCHEMBL24155857 | 0.87 | VDR (0.45) | CXCR4TNFSF11CACNA1BVDRSSTR2 | |
| SCHEMBL25758456 | 0.81 | ESR1 (0.51) | — | |
| SCHEMBL29615096 | 0.66 | TSLP (0.62) | SSTR2SSTR1SSTR4SSTR3SSTR5 | |
| SCHEMBL23351361 | 0.65 | F11 (0.48) | F12F11 | |
| SCHEMBL25455142 | 0.64 | KEAP1 (0.53) | CACNA1BSSTR2SSTR1SSTR4SSTR3 | |
| SCHEMBL18767060 | 0.64 | TNFSF11 (0.48) | TNFSF11CACNA1BSSTR2SSTR1SSTR4 | |
| SCHEMBL19545700 | 0.63 | KDM1A (0.69) | SSTR2SSTR4SSTR3SSTR5F11 | |
| SCHEMBL18767061 | 0.62 | CSNK2A2 (0.48) | TNFSF11CACNA1BSSTR2SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VITEK, MICHAEL PETER | 2023-07-06 | — | — | US | disclosed |
| WO-2021263069-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | LI FENGQIAO (US) | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210939-A1 | CYCLIC PEPTIDE COMPOUNDS AND METHODS OF USE | VIP, NPPA, IAPP | CXCR4 327/4885TNFSF11 1198/4885CACNA1B 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.